Samvad Partners advised PlasmaGen BioSciences (P) Ltd on its Series F fundraising of INR 150 crores.

The transaction involved a primary issuance to a consortium of Series F investors, including institutional and angel participants, with Vins Bioproducts Limited joining as the lead investor.

Plasmagen is a specialised player in the plasma products ecosystem, engaged in the manufacture and contract manufacture of plasma-derived products, as well as the import, storage, sale and distribution of blood plasma products in India and overseas. Notably, Plasmagen is among the very few entities in India licensed by the Drug Controller General of India (DCGI) to collect recovered plasma from blood banks, placing it at a critical intersection of regulation, healthcare infrastructure and life-saving therapeutics.

The transaction is also distinctive for the participation of a strategic pharmaceutical investor on financial-investor terms, reflecting confidence in Plasmagen’s platform, regulatory moat and long-term growth trajectory in the immunobiologicals and plasma-derived therapeutics space. We are delighted to have supported Plasmagen through this important growth milestone and look forward to seeing the Company scale its impact in India and global markets.